Open AccessEpoetin alpha reduces cisplatin induced nephrotoxicity in rats
Author(s) -
Dimče Zafirov,
Jasmina Trojachanec,
Nikola Labachevski,
Petraki Korneti,
Svetlana Cekovska,
Igor Kikerkov,
Emilija Atanasovska,
Kalina Georgievska,
Stojmir Petrov
Publication year - 2006
Publication title -
makedonsko farmacevtski bilten/makedonski farmacevtski bilten
Language(s) - English
Resource type - Journals
eISSN - 1857-8969
pISSN - 1409-8695
DOI - 10.33320/maced.pharm.bull.2006.52.006
Subject(s) - nephrotoxicity , cisplatin , medicine , pharmacology , drug , epoetin alfa , erythropoietin , anemia , alpha (finance) , kidney , chemotherapy , surgery , construct validity , patient satisfaction
Clinical efficacy of cisplatin as antitumorous drug is indisputable; but its use is dose-limited due to its association with severe nephrotoxicity. The latest researches have demonstrated that epoetin alpha might have an important role not only in therapeutic aims for correction of different types of anemia, but in could also be efficient as neuroprotective, hepatoprotective, cardioprotective and especially as nephroprotective drug in neprhotoxicity induced by agents based on platinum. The main aim of this study was to determine the effect of epoetin alpha in prevention of nephrotoxicity induced experimentally in Wistar rats by long-term administration of cisplatin at dose of 2 mg/kg/b.w./per week during a period of 8 weeks. The results obtained have shown that epoetin alpha significantly alleviates the functional renal failure induced by long-term administration of cisplatin and improves the general condition as well as reduces the mortality in examined animals.